Treffer: The predictive edge: modeling and simulation in drug product development.

Title:
The predictive edge: modeling and simulation in drug product development.
Authors:
Konagurthu S; Thermo Fisher Scientific, 62925 NE 18th Street, Bend, OR 97701, USA. Electronic address: sanjay.konagurthu@thermofisher.com., Ranathunga DTS; Thermo Fisher Scientific, 62925 NE 18th Street, Bend, OR 97701, USA., Buchanan S; Thermo Fisher Scientific, 62925 NE 18th Street, Bend, OR 97701, USA., Mehta NM; Thermo Fisher Scientific, 62925 NE 18th Street, Bend, OR 97701, USA., Reynolds T; Thermo Fisher Scientific, 62925 NE 18th Street, Bend, OR 97701, USA.
Source:
Advanced drug delivery reviews [Adv Drug Deliv Rev] 2026 Mar; Vol. 230, pp. 115784. Date of Electronic Publication: 2026 Jan 25.
Publication Type:
Journal Article; Review
Language:
English
Journal Info:
Publisher: Elsevier Science Publishers, B.V Country of Publication: Netherlands NLM ID: 8710523 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8294 (Electronic) Linking ISSN: 0169409X NLM ISO Abbreviation: Adv Drug Deliv Rev Subsets: MEDLINE
Imprint Name(s):
Original Publication: Amsterdam : Elsevier Science Publishers, B.V., c1987-
Contributed Indexing:
Keywords: AI/ML; Drug development; Formulation; Pharmacokinetics; Predictive stability; Process modeling; Solubility and bioavailability
Entry Date(s):
Date Created: 20260127 Date Completed: 20260207 Latest Revision: 20260207
Update Code:
20260208
DOI:
10.1016/j.addr.2026.115784
PMID:
41592638
Database:
MEDLINE

Weitere Informationen

It is well-known that drug development is challenging and a time- and resource-intensive endeavor. Historically, it has relied heavily on trial-and-error, empirical approaches that yield a low probability of success. Despite continuous efforts to improve efficiency across the development stages the overall success rate from clinical trial initiation to market approval remains low. In response to these challenges, in-silico predictive modeling and simulations are becoming indispensable tools for accelerating and de-risking the drug product development process. These computational methods use simulated and real-world data to guide decision-making across the entire development pipeline. Notably, these tools are now gaining widespread acceptance not only in discovery but also across the delivery and formulation stages of drug development. Advances in artificial intelligence (AI) and machine learning (ML) are proving transformative, enabling rapid analysis of large datasets and the development of predictive models that enhance classification, prediction, and optimization capabilities across the drug product development process. This review provides an overview of the various in-silico predictive modeling and simulation techniques for drug product development, emphasizing the use of AI/ML, and their applications in drug delivery. We highlight their role in improving drug performance, manufacturability, stability, safety, and overall success from clinical development through commercialization.
(Copyright © 2026 Elsevier B.V. All rights reserved.)

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.